Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An efficacy and safety trial of D22-directed CAR-T (22-CAR-T) cell therapy in Paediatric patients with refractory or relapsed B cell acute lymphoblastic leukemia (rrB-ALL)

Trial Profile

An efficacy and safety trial of D22-directed CAR-T (22-CAR-T) cell therapy in Paediatric patients with refractory or relapsed B cell acute lymphoblastic leukemia (rrB-ALL)

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Anti-CD22-chimeric-antigen-receptor-T-cell-therapy-Shanghai-Yake-Biotechnology (Primary)
  • Indications B-cell leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 03 Aug 2018 New trial record
    • 16 Jun 2018 Results published in the European Hematology Association Media Release
    • 16 Jun 2018 Results published in the European Hematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top